EU approved one-fifth-dose on Monkeypox vaccination due to shortage
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
- Kochi University pioneers outpatient bladder cancer treatment using semiconductor lasers
- ASPEN 2024: Nutritional Therapy Strategies for Cancer and Critically Ill Patients
- Which lung cancer patients can benefit from neoadjuvant immunotherapy?
- Heme Iron Absorption: Why Meat Matters for Women’s Iron Needs
- “Miracle Weight-loss Drug” Semaglutide Is Not Always Effective
EU approved one-fifth-dose on Monkeypox vaccination due to shortage
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
EU approved one-fifth-dose on Monkeypox vaccination due to shortage.
The monkeypox vaccine is in short supply, and the EU supports the “one-to-five” injection method.
On August 20. The European Medicines Agency, the EU regulator, announced on the 19th that in view of the limited supply of monkeypox vaccine produced by the Nordic company in Bavaria, Denmark, European countries may consider reducing the single dose of the vaccine to expand the scope of vaccination and reduce the number of vaccines.
Vaccination is also effective in preventing infection.
The European Medicines Agency recommends the use of the “one-in-five” injection method, that is, individuals receive two intradermal injections of monkeypox vaccine, about 4 weeks apart, with a single dose of one-fifth of the original dose.
Given the current shortage of monkeypox vaccines, governments may decide to reduce vaccinations as a “temporary measure” to protect susceptible groups, the European Medicines Agency said.
European Commissioner for Health and Food Safety Stella Kyriakidis said in a statement that the injection method could expand the number of people vaccinated against the original monkeypox vaccine in Europe. 5 times, “to ensure that people and health care workers at risk of infection are more likely to receive vaccines.”
The European Medicines Agency’s injection recommendations are based on a controlled study of the performance of different doses of monkeypox vaccine.
In about 500 adults, individuals who received one-fifth of the intradermal dose of the vaccine produced antibody levels similar to those who received the original dose of the vaccine subcutaneously.
The monkeypox vaccine was originally administered subcutaneously.
The European Medicines Agency reminds that individuals are more likely to experience redness and changes in skin color after switching to intradermal injections.
Earlier this month, the U.S. Food and Drug Administration approved a similar injection to expand the vaccine supply.
The practice of splitting vaccines to expand supplies has been used during yellow fever and polio outbreaks, according to the Associated Press.
The Associated Press believes that it is unusual for European and American drug regulatory agencies to recommend “one-to-five” vaccination, indicating that the global monkeypox vaccine is extremely scarce.
According to Reuters, the United Kingdom, Canada and Germany are currently allowing only one dose of the monkeypox vaccine to expand vaccination coverage.
The monkeypox vaccine produced by Nordic Bavaria was originally developed to prevent infection with the smallpox virus. Based on experimental data, the European Medicines Agency approved the vaccine in July to prevent monkeypox virus. The World Health Organization previously estimated that the vaccine was 85 percent effective against monkeypox virus.
The company expects a total supply of 16 million doses of monkeypox vaccine this year.
More than 40,000 monkeypox cases have been reported globally since May, half of them in Europe. WHO declared the monkeypox outbreak a “public health emergency of international concern” on July 23
EU approved one-fifth-dose on Monkeypox vaccination due to shortage
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
